NovaBay Pharmaceuticals (NYSE:NBY) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note published on Monday. The brokerage issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Down 4.4 %

NYSE NBY opened at $0.60 on Monday. The company’s 50 day moving average is $0.66 and its 200-day moving average is $0.63. The firm has a market cap of $3.19 million, a P/E ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $9.08.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.